Prognostic value of inflammation or granuloma after intravesival BCG in non-muscle-invasive bladder cancer

被引:22
作者
Jallad, Samer [1 ]
Goubet, Stephanie [2 ]
Symes, Andrew [1 ]
Larner, Timothy [1 ]
Thomas, Philip [1 ]
机构
[1] Brighton & Sussex Univ Hosp, Dept Urol, Brighton, E Sussex, England
[2] Royal Sussex Cty Hosp, Clin Invest & Res Unit, Brighton BN2 5BE, E Sussex, England
关键词
intravesical BCG; prognostic value; inflammation; bladder cancer; granuloma; BACILLUS-CALMETTE-GUERIN; THERAPY; METAANALYSIS; RECURRENCE; CARCINOMA; TRIALS; TUMORS;
D O I
10.1111/bju.12334
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective To evaluate the prognostic value of inflammation or granuloma after intravesical bacille Calmette-Guerin (BCG) treatment in non-muscle-invasive bladder cancer (NMIBC). Materials and Methods Patients with NMIBC treated with intravesical BCG over a 5-year period were identified. The correlations between histopathological results and disease recurrence and progression were assessed, with survival analysis performed using the Kaplan-Meier method. Other relevant variables were also evaluated using univariate and multivariate analysis. A log-rank test was performed to compare time-to-event between groups. Results A total of 215 patients were treated with BCG for NMIBC and the median follow-up was 32 months. Granuloma was identified in 60 patients and inflammation in 125 patients. In 18 patients there was no evidence of either (normal histology group). A total of 12 patients did not have biopsies and were subsequently excluded. The mean recurrence-free survival rate was significantly higher in the granuloma and inflammation groups (65 months [95% CI: 58-72] and 56 months [95% CI: 49-63], respectively) than in the normal histology group (20 months [95% CI: 6-34]; log-rank P < 0.001). On the multivariate analysis, the absence of inflammation/granuloma was significantly associated with recurrence (log-rank P < 0.001). The progression-free survival rate was higher in the granuloma and inflammation groups (75 months [95% CI: 71-79] and 82 months [95% CI: 78-86], respectively) compared with the normal histology group (33 months [95% CI: 17-48]; log-rank P < 0.001). On multivariate analysis, the absence of inflammation/granuloma was significantly associated with recurrence (log-rank P < 0.001). Conclusion Inflammation or granuloma in histology samples after intravesical BCG treatment for NMIBC are positive markers of response and their absence increases the risk of recurrence and progression.
引用
收藏
页码:E22 / E27
页数:6
相关论文
共 24 条
[1]   BCG immunotherapy of bladder cancer: 20 years on [J].
Alexandroff, AB ;
Jackson, AM ;
O'Donnell, MA ;
James, K .
LANCET, 1999, 353 (9165) :1689-1694
[2]   EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder, the 2011 Update [J].
Babjuk, Marko ;
Oosterlinck, Willem ;
Sylvester, Richard ;
Kaasinen, Eero ;
Boehle, Andreas ;
Palou-Redorta, Juan ;
Roupret, Morgan .
EUROPEAN UROLOGY, 2011, 59 (06) :997-1008
[3]   CLINICAL-VALUE OF PATHOLOGICAL-CHANGES AFTER INTRAVESICAL BCG THERAPY OF SUPERFICIAL BLADDER-CANCER [J].
BASSI, P ;
MILANI, C ;
MENEGHINI, A ;
GARBEGLIO, A ;
ARAGONA, F ;
ZATTONI, F ;
PALMA, PD ;
REBUFFI, A ;
PAGANO, F .
UROLOGY, 1992, 40 (02) :175-179
[4]   Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin:: Multivariate analysis of data from four randomized CUETO trials [J].
Fernandez-Gomez, Jesus ;
Solsona, Eduardo ;
Unda, Miguel ;
Martinez-Pineiro, Luis ;
Gonzalez, Marcelino ;
Hernandez, Rafael ;
Madero, Rosario ;
Ojea, Antonio ;
Pertusa, Carlos ;
Rodriguez-Molina, Jesus ;
Emilio Camacho, Jose ;
Isorna, Santiago ;
Rabadan, Mariano ;
Astobieta, Ander ;
Montesinos, Manuel ;
Muntanola, Pedro ;
Gimeno, Anabel ;
Blas, Miguel ;
Antonio Martinez-Pineiro, Jose .
EUROPEAN UROLOGY, 2008, 53 (05) :992-1002
[5]  
Fine PE., 1999, Issues relating to the use of BCG in immunization programmes: a discussion document
[6]   The Role of Bacillus Calmette-Guerin in the Treatment of Non-Muscle-Invasive Bladder Cancer [J].
Gontero, Paolo ;
Bohle, Andreas ;
Malmstrom, Per-Uno ;
O'Donnell, Michael A. ;
Oderda, Marco ;
Sylvester, Richard ;
Witjes, Fred .
EUROPEAN UROLOGY, 2010, 57 (03) :410-429
[7]   Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials [J].
Han, Rui Fa ;
Pan, Jian Gang .
UROLOGY, 2006, 67 (06) :1216-1223
[8]  
HENEY NM, 1992, UROL CLIN N AM, V19, P429
[9]   EXPERIENCE WITH INTRAVESICAL BACILLUS CALMETTE-GUERIN THERAPY OF SUPERFICIAL BLADDER-TUMORS [J].
HERR, HW ;
PINSKY, CM ;
WHITMORE, WF ;
SOGANI, PG ;
OETTGEN, HF ;
MELAMED, MR .
UROLOGY, 1985, 25 (02) :119-123
[10]   Maintenance therapy with bacillus Calmette-Guerin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer [J].
Hinotsu, Shiro ;
Akaza, Hideyuki ;
Naito, Seiji ;
Ozono, Seiichiro ;
Sumiyoshi, Yoshiteru ;
Noguchi, Sumio ;
Yamaguchi, Akito ;
Nagamori, Satoshi ;
Terai, Akito ;
Nasu, Yasutomo ;
Kume, Haruki ;
Tomita, Yoshihiko ;
Tanaka, Yoshinori ;
Samma, Shoji ;
Uemura, Hirotsugu ;
Koga, Hirofumi ;
Tsushima, Tomoyasu .
BJU INTERNATIONAL, 2011, 108 (02) :187-195